Exelixis (EXEL) reported Q4 earnings of 37 cents per share and revenue of $228.6 million that beat analysts’ views. Analysts had expected the drug discovery company to earn 24 cents per share on revenue of $189 million. Exelixis stock rose about 5% during the extended trading hours on Tuesday.
The Alameda, California-based biotech company’s GAAP EPS surged to $1.15 from $0.13 reported in the prior year quarter, helped by the increases in net product and collaboration revenues.
For 2019, Exelixis expects R&D expenses to be between $285 million and $315 million. Selling, general and administrative expenses are expected to be between $220 million and $240 million.
“Exelixis achieved strong financial performance in 2018, with solid growth in cabozantinib net product revenue, total revenue, and importantly, earnings per share and cash on hand,” said CEO Michael Morrissey.
Related: Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump
In January 2019, Exelixis announced the FDA approval of cancer drug CABOMETYX for the treatment of patients with a type of liver cancer who have been previously treated with sorafenib drug.
In January 2019, Exelixis’ partner Daiichi Sankyo received approval from the Japanese Ministry of Health, Labour and Welfare for MINNEBRO tablets, which will treat patients with hypertension.
As per the collaboration agreement with Daiichi Sankyo, Exelixis will receive $20 million as a milestone payment upon the first commercial sale of MINNEBRO in Japan. Exelixis is also eligible for additional commercialization milestone payments, as well as low double-digit royalties on sales of MINNEBRO.
Exelixis also announced today that it is initiating the phase 1 clinical development for XL092, a drug to treat patients with advanced solid tumors.
Shares of Exelixis ended Tuesday’s session at $21.68, up 3.34%. The stock had gained 10% since the beginning of 2019.
We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips
Most Popular
Infographic: Key metrics from Estee Lauder’s (EL) Q3 2024 earnings results
The Estee Lauder Companies Inc. (NYSE: EL) reported its third quarter 2024 earnings results today. Net sales were $3.94 billion, up 5% from the prior-year quarter. Organic sales increased 6%.
YUM Earnings: Key quarterly highlights from Yum! Brands’ Q1 2024 financial results
Yum! Brands, Inc. (NYSE: YUM) reported first quarter 2024 earnings results today. Total revenues decreased 3% year-over-year to $1.59 billion. Same-store sales declined 3%. Net income increased 5% to $314
Pfizer (PFE) Q1 2024 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported first quarter 2024 earnings results today. Revenues decreased 20% year-over-year to $14.8 billion. Reported net income declined 44% to $3.1 billion, or $0.55 per share,
